High eosinophil count: A potential biomarker for assessing successful omalizumab treatment effects William Busse, MD, Sheldon Spector, MD, Karin Rosén,

Slides:

Advertisements

Similar presentations

Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.

Advertisements

Biologics in Asthma—The Next Step Toward Personalized Treatment

D-dimer: A biomarker for antihistamine-resistant chronic urticaria

Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered- dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder.

Simultaneously increased fraction of exhaled nitric oxide levels and blood eosinophil counts relate to increased asthma morbidity Andrei Malinovschi,

Risk of an asthma exacerbation after bariatric surgery in adults

Reduced exhaled nitric oxide values in children with asthma after inpatient rehabilitation at high altitude Johannes Huss-Marp, MD, Ursula Krämer, PhD,

Anne M. Fitzpatrick, PhD, MSCR, W. Gerald Teague, MD

Alalia Berry, MD, William W. Busse, MD

Fatty acids, inflammation, and asthma

A cluster-randomized trial to provide clinicians inhaled corticosteroid adherence information for their patients with asthma L. Keoki Williams, MD, MPH,

The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD

Stephen J. Fowler, MD, Gaël Tavernier, PhD, Robert Niven, MD

Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD

Incident asthma and Mycoplasma pneumoniae: A nationwide cohort study

Is 9 more than 2 also in allergic airway inflammation?

Fatty acids, inflammation, and asthma

Joe K. Gerald, MD, PhD, Roni Grad, MD, William C. Bailey, MD, Lynn B

Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy Allen Kaplan, MD, Dennis Ledford,

Badrul A. Chowdhury, MD, PhD

NAEPP Expert Panel Report

Rising prevalence of asthma is sex-specific in a US farming population

Lieuwe D. Bos, MSc, PhD, Peter J. Sterk, MD, PhD, Stephen J

A randomized multicenter study evaluating Xolair persistence of response after long- term therapy Dennis Ledford, MD, William Busse, MD, Benjamin Trzaskoma,

Asthma Exacerbations and Triggers in Children in TENOR: Impact on Quality of Life Bradley E. Chipps, MD, Tmirah Haselkorn, PhD, Karin Rosén, MD, PhD,

The risk of asthma exacerbation after stopping low-dose inhaled corticosteroids: A systematic review and meta-analysis of randomized controlled trials

Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis George Philip, MD, Janet van Adelsberg, MD, Thomas Loeys, PhD, Nancy.

Reply Journal of Allergy and Clinical Immunology

Physician needs in health informatics: Just ask the docs

Treatment of chronic autoimmune urticaria with omalizumab

A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine–refractory chronic idiopathic urticaria

Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study Thomas B. Casale, MD, Allan.

Peter M. Wolfgram, MD, David B. Allen, MD

William J. Calhoun, MD, Tmirah Haselkorn, PhD, Dave P

An age-dependent association of mannose-binding lectin-2 genetic variants on HIV-1– related disease in children Kumud K. Singh, PhD, Alexis Lieser, MD,

Jewlya Lynn, PhD, Sophie Oppenheimer, MS, MPH, Lorena Zimmer, MA

Approaches to the diagnosis and management of patients with a history of nonsteroidal anti-inflammatory drug–related urticaria and angioedema Marek L.

Jon Genuneit, MD, MSc Journal of Allergy and Clinical Immunology

Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation Leif Bjermer, MD Journal of Allergy.

What are the best outcome measurements for atopic eczema

Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management Scott H. Sicherer, MD, Hugh A. Sampson, MD Journal.

Biosimilars and drug development in allergic and immunologic diseases

Nicola A. Hanania, MB BS, MS, Bradley E. Chipps, MD, Noelle M

The status of US allergy/immunology physicians in the 21st century: A report from the American Academy of Allergy, Asthma & Immunology Workforce Committee

Daphne Koinis-Mitchell, PhD, Timothy Craig, DO, Cynthia A

A cluster-randomized trial shows telephone peer coaching for parents reduces children's asthma morbidity Jane M. Garbutt, MB, ChB, Yan Yan, MD, PhD,

Claus Bachert, MD, PhD, Cezmi A. Akdis, MD

What is an “eosinophilic phenotype” of asthma?

H. William Kelly, PharmD Journal of Allergy and Clinical Immunology

Autophagy: Nobel Prize 2016 and allergy and asthma research

Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment

Advances in the approach to the patient with food allergy

Geographic variability in childhood asthma prevalence in Chicago

High prevalence of severe asthma in a large random population study

Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered- dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder.

A single intervention for cockroach control reduces cockroach exposure and asthma morbidity in children Felicia A. Rabito, PhD, MPH, John C. Carlson,

Erick Forno, MD, MPH, Yueh-Ying Han, PhD, Radhika H

Syk expression and IgE-mediated histamine release in basophils as biomarkers for predicting the clinical efficacy of omalizumab Donald W. MacGlashan,

Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids Michael Noonan, MD, Phillip Korenblat, MD, Sofia Mosesova, PhD,

Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab Aidan Long, MD, Abdelkader Rahmaoui, MD, Kenneth.

Jessica H. Savage, MD, MHS, Elizabeth C. Matsui, MD, MHS, Robert A

Pınar Uysal, MD, Esben Eller, MSc, PhD, Charlotte G

Measles and immunomodulation

Macrolide antibiotics and asthma treatment

Statistical issues in clinical trials that involve the double-blind, placebo-controlled food challenge Vernon M. Chinchilli, PhD, Laura Fisher, MD, Timothy.

Asthma: The past, future, environment, and costs

Environmental factors and eosinophilic esophagitis

Natural history of cow’s milk allergy

Primary prevention of asthma and allergy

Presentation transcript:

High eosinophil count: A potential biomarker for assessing successful omalizumab treatment effects William Busse, MD, Sheldon Spector, MD, Karin Rosén, MD, PhD, Yan Wang, PhD, MPH, Oral Alpan, MD Journal of Allergy and Clinical Immunology Volume 132, Issue 2, Pages 485-486.e11 (August 2013) DOI: 10.1016/j.jaci.2013.02.032 Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 1 Rate ratio (95% CI) of protocol-defined asthma exacerbation by subgroup. Journal of Allergy and Clinical Immunology 2013 132, 485-486.e11DOI: (10.1016/j.jaci.2013.02.032) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig E1 Patient disposition. ∗Five patients were found to be ineligible after enrollment. Journal of Allergy and Clinical Immunology 2013 132, 485-486.e11DOI: (10.1016/j.jaci.2013.02.032) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig E2 Least squares means of relative change from baseline in FEV1 (mITT population [excluding 1 patient with outlying spirometry data]). LSM, Least squares means (adjusted for dosing regimen and prior exacerbation status). *P = .04; †P = .002; ‡P = .02; **P = .008. Journal of Allergy and Clinical Immunology 2013 132, 485-486.e11DOI: (10.1016/j.jaci.2013.02.032) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig E3 Rate ratio (95% CI) of protocol-defined asthma exacerbation by prior exacerbation status and dosing regimen subgroups. Q2, every 2 wk; Q4, every 4 wk. Journal of Allergy and Clinical Immunology 2013 132, 485-486.e11DOI: (10.1016/j.jaci.2013.02.032) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig E4 Least squares means of relative change from baseline in FEV1 (mITT population). LSM, Least squares means (adjusted for dosing regimen and prior exacerbation status). *P = .02; †P = .001; ‡P = .01; **P = .009. Journal of Allergy and Clinical Immunology 2013 132, 485-486.e11DOI: (10.1016/j.jaci.2013.02.032) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions